AG
MRNA icon

Ascent Group’s Moderna MRNA Stock Holding History

Ascent Group’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,679
Closed -$411K – 484
2023
Q1 		$411K Buy
2,679
+486
+22% +$80.2K 0.04% 342
2022
Q4 		$394K Buy
2,193
+21
+1% +$3.43K 0.05% 342
2022
Q3 		$327K Buy
2,172
+495
+30% +$75.1K 0.04% 360
2022
Q2 		$275K Sell
1,677
-805
-32% -$115K 0.03% 407
2022
Q1 		$428K Buy
+2,482
New +$418K 0.05% 339

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Ascent Group's MRNA Position: Q2 2023 in Review

Ascent Group sold out of Moderna (MRNA) in Q2 2023, closing a stake of 2,679 shares — an estimated $411K sold.

Ascent Group first reported a position in MRNA in Q1 2022 and held it in 5 quarters. The position peaked at $428K in Q1 2022. 965 funds tracked by Wall St. Rank hold MRNA as of Q2 2023.

  • Ascent Group reported no remaining Moderna position as of Q2 2023 after selling out during the quarter.
  • Ascent Group sold 2,679 Moderna shares in Q2 2023, an estimated $411K.
  • Ascent Group first reported a position in Moderna in Q1 2022 and held it in 5 quarters.
  • Ascent Group's Moderna position peaked at $428K in Q1 2022.
  • 965 funds tracked by Wall St. Rank held Moderna as of Q2 2023.

Based on Ascent Group's 13F filing for Q2 2023, filed 14 Aug 2023.